Clinical Trial Update: Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with PD-1 inhibitor and gemcitabine plus cisplatin for unresectable or metastatic biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• PD-1 inhibitor

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN